Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06735924 · ClinicalTrials.gov registry record · NA
Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis
A NA study of MASLD and Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06735924: Recruiting NA study of MASLD and Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by University of Alabama at Birmingham.
NCT06735924 is a NA study of MASLD and Metabolic Dysfunction Associated Steatotic Liver Disease that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 28 participants, below the 109-participant average among 7 other MASLD trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06735924, a NA study of MASLD and Metabolic Dysfunction Associated Steatotic Liver Disease, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Primary Outcome
Average fasted hourly urinary oxalate excretion rate normalized to urinary creatinine excretion (mg oxalate / g urinary creatinine)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Low-oxalate fixed diet
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-04-26 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06735924 shows while recruiting
NCT06735924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 109-participant average among 7 other MASLD trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with MASLD appearing as the primary indexed condition, and to 1 intervention - of which Low-oxalate fixed diet is the first listed.
NCT06735924 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06735924 about?
NCT06735924 is a clinical study titled "Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis". This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
What is the current status of trial NCT06735924?
This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2023-04-26. Estimated completion is 2027-12-31.
What conditions does trial NCT06735924 study?
This clinical trial studies the following conditions: MASLD, Metabolic Dysfunction Associated Steatotic Liver Disease.
What interventions are being tested in trial NCT06735924?
The interventions under investigation include: Low-oxalate fixed diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06735924?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06735924 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MASLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
NAFLD Clinical Care Pathway
RECRUITING · NA
-
Endoscopic Ultrasound Shear Wave Elastography Study
RECRUITING
-
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
RECRUITING · Early Phase 1
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI